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Tumour-initiating cells (TICs) are rare cancer cells isolated from tumours of different origins including highgrade tumours that sustain neoplasic progression and development of metastatic disease. They harbour deregulated stem cells pathways and exhibit an unchecked ability to self-renew, a property essential for tumour progression. Among the essential factors maintaining embryonic stem (ES) cells properties, OCT-4 (also known as POU5F1) has been detected in tumours of different origins. Although ectopic expression results in dysplasic growth restricted to epithelial tissues, overexpression expands the proportion of immature cells in teratomas. However, OCT-4-expressing cells have not been purified from spontaneously occurring tumours, thus information concerning their properties is rather scant. Here, using p53À/À mice expressing green fluorescent protein and the puromycin resistance gene under the control of the Oct-4 promoter, we show that OCT-4 is expressed in 5% onwards of the undifferentiated tumour cell populations derived from different organs. OCT-4 expression was low as compared with ES cells, but was associated with a 'stemness' signature and expression of the chemokine receptor CXCR4. These cells displayed cancer stem cell features, including increased self-renewal and differentiation ability in vitro and in vivo. They not only formed allografts containing immature bone regions but also disseminated into different organs, including lung, liver and bone. Experiments based on RNA interference revealed that Oct-4 expression drives both their engraftment and metastasis formation. This work points out the crucial contribution of Oct-4-expressing TICs in the hierarchical organization of the malignant potential, leading to metastasis formation. Consequently, it provides an appropriate model to develop novel therapies aiming to strike down TICs by targeting self-renewal genes,
Introduction
Tumour tissues are known to consist of a heterogeneous cellular population containing a minor population of proliferating cells and a major population of differentiated cells with limited proliferation potential. Among the proliferating cells, cancer stem cells (CSCs), also called tumour-initiating cells (TICs), are able to self-renew, drive the tumourigenic potential, produce the different lineages that comprise the tumour (Diehn et al., 2009; Shackleton et al., 2009) and have a crucial role in tumour metastasis (Nguyen et al., 2009; Monteiro and Fodde, 2010) . On the basis of cell-surface marker expression, CSCs were first isolated from leukaemia (Bonnet and Dick, 1997) and then from different solid tumours upon expression of CD44 (AlHajj et al., 2003; Li et al., 2007) or CD133 (Singh et al., 2004; O'Brien et al., 2007; Ricci-Vitiani et al., 2007) . These approaches revealed the diversity and heterogeneity of these populations and had a major impact on characterization of their tumourigenic and metastatic potential. However, information on the mechanisms underlying these properties is rather scant.
Oct-4 (also known as Pou5f1) is a transcription factor belonging to the POU-domain family. In the developing embryo, its expression is limited to the cells of the epiblast and to primordial germ cells (Nichols et al., 1998) . Proper development requires a strict control of Oct-4 expression, as loss of function induces differentiation of the epiblast into the trophectoderm and overexpression leads to differentiation into extra-embryonic mesoderm and endoderm (Niwa et al., 2000) . In adults, Oct-4 expression is associated with abnormal developmental processes. It governs malignant potential of germ-tumour cells (Gidekel et al., 2003) . Its controlled and inducible ectopic expression produces dysplasia restricted to the epithelial tissues that is reversed upon inducer withdrawal (Hochedlinger et al., 2005) . Therefore, Oct-4 behaves as an oncogene. Oct-4 is expressed in high-grade tumours of different origins, including breast, brain and colon (Clement et al., 2007; BenPorath et al., 2008; Ruiz i Altaba and Brand, 2009) , in association with Nanog and Sox2, two other major intrinsic determinants of embryonic stem (ES) cells, essential to maintain their pluripotent state (Chambers et al., 2007; Masui et al., 2007) . This 'stemness' signature is always associated with a poor prognosis in tumours as different as glioblastomas or adenocarcinomas. Its functional significance is not reported because expressing cells have not been characterized.
On the basis of these observations, we hypothesized that cells expressing Oct-4 within tumours may represent TICs displaying properties consistent with an unrestricted location. To purify cells expressing Oct-4 and to characterize them, we developed a model allowing direct purification of Oct-4-expressing cells from different types of tumours. We used p53À/À mice (Donehower et al., 1992) carrying an Oct-4-GiP transgene to allow expression of green fluorescent protein (GFP) and puromycin resistance gene under the control of Oct-4 promoter, without interfering with endogenous Oct-4 expression (Ying et al., 2002) . Here, we show that cells expressing Oct-4 can be isolated from tumours of different origins that developed spontaneously. These cells displayed characteristics of CSCs associated with CXCR4 expression, a protein implicated in cellular migration, high malignant potential and metastasis (Muller et al., 2001; Gassmann et al., 2009; Huang et al., 2009) . Experiments based on RNA interference showed that Oct-4 expression directly supported their tumourigenic potential. Furthermore, these cells produced allografts that contained immature bone cells, and they were able to disseminate into different organs. Thus, they not only displayed tumour-initiating properties but also endowed tumour metastasis potential.
Results
Design of a mouse model to isolate Oct-4-expressing cells from mouse tumours p53À/À mice carrying the Oct-4-GiP transgene were selected after genotyping (see Supplementary Information) and allowed to age until they developed tumours. The tumours obtained recapitulate the different types previously described in p53 knockout mice (Donehower et al., 1992) . The present study focuses only on solid tumours (Supplementary Table 1) .
The presence of Oct-4-expressing cells within tumours was first assessed by GFP expression by using flow cytometry after dissociation of the tumour tissue. Oct-4-expressing cells represent 5.22±0.31% (n ¼ 6) of the total population (range comprised between 1% and 8.9%). This indicates that the Oct-4 promoter is active.
GFP-positive cells displayed heterogeneous expression patterns for CD133, CD44 and CXCR4 in different tumours, and thus could not be purified in a reliable manner according to these markers (Supplementary Figure 1) . Furthermore, high mortality was observed after fluorescence-activated cell sorting of these cells upon GFP expression, therefore this approach was not pursued for further characterization.
Using appropriate culture conditions to grow ES cells and to retain Oct-4 expression, 14 out of 25 tumours could be maintained in culture. GFP-positive cells were detected in all the cultures (Supplementary Table 1) , with a proportion ranging between 3.1% and 5.5% (Supplementary Table 2 ). After puromycin selection, Oct-4-expressing cells were obtained only from six of them, probably because of a too low expression of the Oct-4-GiP transgene in some cells. They derived from tumours of different origins: three subcutaneous tumours, two lung tumours and one undifferentiated gut tumour (Supplementary Table 1 ). The continuous presence of puromycin was necessary to maintain this population. Upon withdrawal, most of the cells lost GFP expression and re-application of puromycin allowed selection again. Further work was carried out on cells obtained from tumours designated as A (mesenchymal), B (adenocarcinoma), C (gut) and D (lung) (Supplementary Table 1 ).
Properties of Oct-4-expressing cells
Properties of the Oct-4-expressing cells relative to the cell population of the whole tumour were then analysed. The expression of markers specific for ES cells Oct-4 and Nanog was barely detectable in non-selected cells, irrespective of the tumour origin but was significantly increased in the puromycin-selected cells in three tumours out of four ( Figures 1A-C) . Oct-4 mRNA expression was close to 1 000 times less as compared with expression in murine ES cells. Sox2 mRNA was more readily detected in non-selected cells. Its expression was slightly, but not significantly, increased in puromycin-selected cells from three tumours ( Figures 1A and D) . Expression of OCT-4 protein in GFP-positive cells was confirmed by immunocytochemistry ( Figure 1E ). OCT-4 labelling showed small dots in the nucleus. Clonogenic potential of tumour cells has been measured from the percentage able to form colonies on methylcellulose. Depending on the parental tumour, 5%-9% of the cells were clonogenic before puromycin selection ( Figure 1F ). A higher clonogenic potential was measured in Oct-4-expressing cells as this percentage increased up to 17%-19%, suggesting a higher self-renewal capacity.
Oct-4-expressing cells are tumourigenic and self-renew in vivo We then evaluated the tumourigenic potential of Oct-4-expressing cells by measuring their ability to engraft and generate subcutaneous allografts in severe combined immunodeficient mice (CB17/SCID) for a period of 14 weeks (Table 1A) . Non-selected cells, isolated from the (Table 1b) . Allografts developed with shorter time of onset: only 2 weeks were necessary to observe allograft formation when 10 000 Oct-4-expressing cells from allograft A were injected in CB17/SCID mice, whereas it took 8 weeks for Oct-4-expressing cells from the parental tumour A (Tables 1a and b ). All these observations are fully consistent with an increased aggressiveness of the tumours produced by Oct-4-expressing cells. Genetic analysis of cells injected before or after selection showed aneuploidy for all populations (Supplementary Table 3 ). Chromosome rearrangements assigned to Oct-4-expressing cells were only found in tumour D, which displayed the lowest Oct-4 expression and tumour potential. Thus, the tumour potential of Oct-4-expressing cells cannot just be assigned to consequences of tissue culture conditions.
All these results indicate that independently of the origin of the tumour, Oct-4-expressing cells generate serial allografts, displaying a significantly higher tumourigenic potential as compared with total population of parental tumour cells and a higher propensity to self-renew in vivo. Thus, Oct-4-expressing cells display TIC features. Abbreviation: SCID, severe combined immunodeficient mice. CB17/SCID mice were transplanted subcutaneously with cells obtained from tumours A, B, C and D before (total population) or after (Oct-4 expressing) puromycin selection. For all tumours, cells at passages 5 or 6 were injected to avoid discrepancies due to tissue culture. The number of cells injected, the number of mice developing tumours over the total number of mice injected (Result) and the mean number of weeks (W) necessary to obtain allografts (time) are indicated. Table 1a describes results obtained with injection of cells from parental tumour, whereas Table 1b refers to injection of cells from the allografts. Figure 2) . Thus, some markers displayed similar patterns of expression between parental tumours and allografts, whereas a preferential pattern was observed for others. Allografts exhibited comparable expression patterns for the markers analysed. Taken together, these results indicate that Oct-4-expressing cells induce allografts that recapitulate some but not all the features of the parental tumour. In contrast, allografts obtained after serial transplantation of Oct-4-expressing cells (Figures 2m-p) presented strong similarities with primary allografts (Figures 2e-h ). This observation further confirms the self-renewal potential of these TICs.
Irrespective of the origin of the parental tumour, allografts displayed zones containing alkaline phosphatase activity as assessed by specific staining ( Figures 3A  a-d) . They also exhibited specific labelling for osteocalcin, an osteoblast marker ( Figure 3A e-h ). In vitro, the ability of Oct-4-expressing cells to differentiate into osteoblasts was assessed by positive alizarin red staining, which is specific for calcific deposition ( Figure 3B ) and was accompanied by an increased expression of specific osteoblastic markers, such as Runx2 and alkaline phosphatase (Alpl; Figures 3C and  D) . We never observed adipocytic differentiation (not shown). Thus, Oct-4-expressing cells can respond to some of the biological cues for maturation in vivo and in vitro.
Metastatic capacity of Oct-4-expressing cells
The four tumours analysed were obtained from p53À/À Oct-4-GiP mice that did not present multiple tumour sites (Supplementary Table 1 ). When Oct-4-expressing cells isolated from tumour B were injected in the tail vein of CB17/SCID mice at different concentrations, we detected metastasis formation in the lung and in the thoracic cavity ( Figure 4A ).
The ability to disseminate and to promote metastasis formation was also observed when Oct-4-expressing cells from tumours B and C were injected intraperitoneally (i.p.; Figure 4B and Supplementary Figure 3) . Metastatic nodules were present in different organs of the thorax and the abdomen, including the lung and the liver. Malignant origin was further confirmed by histological analysis of tissue sections ( Figure 4B c and  d, Supplementary Figure 3b) . When compared with allografts, metastatic sections stained with haematoxylin, eosin and safranin displayed similar histology ( Figures 2 and 4 and Supplementary Figure 3) . We never noticed induction of blood malignancies.
High levels of chemokine receptor CXCR4 were found in freshly dissociated GFP-positive cells from primary tumour (Supplementary Figure 1) as well as in cultured Oct-4-expressing cells (Figures 4C and D) . Highest CXCR4 levels were measured in cells from parental tumours B and C that displayed the highest tumour potential (Table 1) . Expression of different isoforms of CXCR4 has been reported (Carlisle et al., 2009) , and this might explain the low amounts of mature protein associated with chemotaxis activity observed in tumour A. Thus, the metastatic potential of Oct-4-expressing cells is correlated with enhanced expression of a protein involved in cell migration.
Oct-4 expression drives the tumourigenic potential
We analysed the importance of Oct-4 expression in sustaining the tumourigenic and metastatic potentials of Oct-4-expressing cells from tumours B and C, using small interfering RNA (siRNA) to Oct-4 (Zeineddine et al., 2006) . Although no significant effect was noticed on cell proliferation, after 3 days of transfection the siRNA reduced Oct-4 mRNA level by 75% in Oct-4-expressing cells ( Figure 5A ). Oct-4 inhibition reduced clonogenicity by 74% for parental tumour B ( Figure 5B , Supplementary Figure 4a) and by 83% for tumour C (Supplementary Figure 5a) , as well as tumour potential. While mice injected with 250 000 Oct-4-expressing cells from tumour B treated with non-relevant siRNAs (control) developed allografts with kinetics similar to non-transfected cells (that is, 15-20 days, Table 1a), the size of the allografts that developed during the same period of time represented 27.5 ± 4.8% (n ¼ 5) when Oct-4 siRNA-treated knockdown cells were injected. This indicated a dramatic decrease in tumour potential ( Figures 5C and D, Supplementary Figures 5b and c) . However, transient inhibition of Oct-4 expression with siRNA treatment delayed, but did not abolish, the tumour potential of these cells as tumours developed within 25 days ( Figure 5D ). Histology of the allografts obtained from non-transfected cells or siRNA-treated cells did not reveal striking differences (Figures 2 and  5C ). Similar results were obtained when two other different siRNAs against Oct-4 (Supplementary Information) were used and with tumour C (Supplementary Figure 6) . Histological analysis showed that short hairpin RNA to Oct-4 dramatically restrained the efficiency of Oct-4-expressing cells to proliferate and to form allografts (Supplementary Figure 6e) .
Transient inhibition of Oct-4 was efficient in decreasing the metastasis induced by these cells. The kinetics of metastasis development was assessed by a bioluminescence assay after i.p. injection of Oct-4 siRNA-treated knockdown cells and Oct-4-expressing cells treated with non relevant siRNA. Although cell dissemination was not completely blocked, metastasis development was slower in Oct-4 siRNA-treated knockdown cells ( Figure 5E ).
Together, these results point out a direct role for Oct-4 in malignant progression and in metastasis as, although low, expression of Oct-4 is sufficient to confer a higher self-renewal capacity, higher tumour potential and metastasis formation in vivo.
Discussion
We have designed an experimental model system to isolate and analyse Oct-4-expressing cells from different tumour types obtained from p53À/À mice. These cells presented all the characteristics of TICs, including the ability to self-renew, the potential to give rise to more mature cells through a differentiation process, the selective capacity to initiate tumours and drive metastasis formation. Most of TICs described so far were isolated upon expression of cell surface markers, such as CD44 and CD133, and this approach contributed to identify cells responsible for the development of several malignant neoplasms (Al-Hajj et al., 2003; Singh et al., 2004; Li et al., 2007; O'Brien et al., 2007; Prince et al., 2007; Ricci-Vitiani et al., 2007) . Although CD44 represents more than a cancer marker because its targeting reverses blockage of differentiation in acute myeloid leukaemia or reduces tumour growth in breast cancer (Charrad et al., 1999; Marangoni et al., 2009) , indeed expression of surface markers is sometimes insufficient to characterize the different populations of CSCs, which are heterogeneous (Beier et al., 2007; Hermann et al., 2007; le Viseur et al., 2008; Wang et al., 2008; O'Brien et al., 2009) . For example, CD133 is not an obligate marker for CSCs in gliomas because CD133-negative cells display tumour potential as well (Harris et al., 2008) . In addition, tumour cells might include TICs with a unique phenotype contributing to the original tumour development and TICs bearing metastatic potential that exhibit a different phenotype acquired after evolution (Shipitsin et al., 2007; Charafe-Jauffret et al., 2009) . Depending on the tumour specimen, expression of CD44 and CD133 was different, (Supplementary Longer time (25 days) was necessary for tumour to develop, when cells treated with siRNA to Oct-4 were injected (c; n ¼ 3). Scale bar, 2 mm. Histological analysis of the allografts shown in lower panels (d-f) confirms that siRNA treatment did not modify histology (scale bar, 100 mm). (D) Quantification of the tumour size. When treated with siRNA to Oct-4, cells produced allografts that were 73% smaller compared with cells treated with non-relevant siRNAs after 17 days (***Po0.001, n ¼ 5). Longer development was necessary to get comparable size (that is, 25 days). (E) siRNA to Oct-4 decreases metastasis formation. CB17/SCID mice were inoculated i.p. with cells from tumour C treated with non-relevant siRNA or siRNA to Oct-4 (250 000 cells). In vivo bioluminescent imaging of light emitted by cells reveals a transitory decrease in the number and size of sites for light emission when cells treated with siRNA to Oct-4 were injected. Figure 1 ), indicating that their presence does not always correlate with Oct-4 expression. Thus, purification of TICs upon cell surface marker expression has limitations and was not convenient to sort Oct-4-expressing cells. Our strategy based on self-renewal gene tracking allowed isolation of a tumour sub-population of cells present in different tumour types from p53À/À mice that was not previously described.
The expression of the Oct-4-GiP reporter in tumour cells correlates with malignant potential and development of allografts, presenting an undifferentiated phenotype in our mouse model. As reported in other models (Al-Hajj et al., 2003; Singh et al., 2004; Li et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007) , these cells represent a minute population among cancer cells. Oct-4 was expressed at low but sufficient levels to confer a higher self-renewal capacity, higher tumourigenic and metastatic potentials in vivo as compared with the population of the whole-tumour cells. This is in agreement with the key role described for Oct-4 in maintaining self-renewal in ES cells (Niwa et al., 2000) . Oct-4-expressing cells clearly differ from ES cells. They do not possess their pluripotent ability and display a limited repertoire of differentiation pathways. Although they retained ability for maturation towards osteoblasts, they did not generate adipocytes. We never noticed development of leukaemia after injection of Oct-4-expressing cells in mice. In agreement with this observation, the ES cell-like program in mixed-lineage leukaemia (MLL) stem cells does not depend on Oct-4, Sox2 and Nanog expressions (Somervaille et al., 2009) .
In bone and soft-tissue tumours, the (6;22)(p21;q12) translocation involving the EWS and the Oct-4 genes generates a fusion protein presenting higher transactivation activity as compared with OCT-4, which is essential to the tumourigenic potential (Lee et al., 2007) . Moreover, within osteosarcoma cell-lines, Oct-4 expression was reported to qualify cells able to form tumour nodules in the lung. But their high tumourigenic potential was acquired after serial xenotransplantations (Levings et al., 2009) . Metastasis formation was observed using Oct-4-expressing cells isolated from primary tumours, indicating that metastatic potential occurred in the context of the primary tumour and did not result from a selective adaptation due to serial passages in vivo.
An ES cell-like gene expression signature has been described in poorly differentiated aggressive human solid tumours arising in various tissues from distinct cell of origin, including the breast, the bladder and the brain (Clement et al., 2007; Ben-Porath et al., 2008) , and was associated with poor prognosis. This signature is also important for the diagnostic of germ cell tumours presenting metastatic potential (Santagata et al., 2007) , and it is interesting to note that all these primary carcinomas display several metastatic sites for relapse, including the bone, the lung and the liver (Rajagopalan et al., 2005; Kaufman, 2006; Nguyen et al., 2009; Zhang et al., 2009) . Recently, the co-expression of Oct4 and Nanog was detected in high-grade and metastatic lesions of patients with lung adenocarcinoma, and overexpression of these two transcription factors in A549 cells induced a shift of their cellular properties towards a state closer to stem cells (Chiou et al., 2010) . This suggested a crucial role for this 'stemness' profile during the course of tumour progression. Expression of Sox2 (but not Oct-4) has been reported in multiple adult tissues (Hochedlinger and Plath, 2009 ). We detected Sox2 in non-selected cells that display a limited tumourigenic potential and in Oct-4-expressing cells. Thus, a major role for Sox2 in the acquisition of malignant potential was unlikely. In contrast, Oct-4 was preferentially expressed in cells endowed with malignancy. Our results and those from the literature indicate that within cells displaying a 'stemness' signature, Oct-4 expression, even low as compared with ES cells, is a major determinant sustaining tumour and metastatic potentials of cells able to disseminate in mice and humans.
This 'stemness' signature was present in our cells associated with CXCR4 expression. CXCR4 is reported to be expressed in many types of rodent and human cancers, where it is also associated with bad prognosis. It has a crucial role in metastasis formation in several types of cancer (Muller et al., 2001; Zeelenberg et al., 2001; Kucia et al., 2005; Hermann et al., 2007) for expressing cells exhibit high propensity to disseminate (Gassmann et al., 2009) . It is to note that CXCR4 ligand CXCL12/SDF-1a is abundant in bone marrow stromal cells (Muller et al., 2001) , allowing homing of CXCR4-positive cells. Therefore, these TICs isolated from tumours of different origins bear fundamental properties of metastatic cells, including migration and invasiveness in vivo, associated with a 'stemness' signature driving the tumour potential by the way of Oct-4 expression. Their purification and characterization allowed identification of cells making up a link between a molecular signature associated with poor prognosis and tumour pathogenesis. Considering that this signature has been assigned to aggressive tumours, these cells, likely, represent one of the highest stages of tumour progression consistent with dissemination of different neoplasms.
The molecular mechanisms causing deregulation of Oct-4 expression in cancer cells and those involved in the acquisition of this highly malignant phenotype remain to be established. They represent an important challenge because disruption of Oct-4 expression after knockdown using RNA interference impaired self-renewal and was detrimental to both tumour and metastasis developments in a p53À/À context. These last observations have to be compared with previous reports showing the regression of tumours observed when ectopic expression of Oct-4 is stopped (Hochedlinger et al., 2005) , when forced downregulation of Oct-4 expression prevents tumour growth in a mouse teratoma model (Gidekel et al., 2003) or when differentiation of dysplasic or neoplasic cells occurs upon loss of oncogene expression (Felsher, 2004; Shachaf et al., 2004; Hutchin et al., 2005) . Indeed, OCT-4 behaves like an essential factor driving both self-renewal and tumourigenic/metastatic potentials in the TICs described here, and any approach aiming to reduce its expression may lead to strategies effective to reduce cancer pathogenesis, with a minimal impact on the function of somatic cells where its expression is barely observed and not required for selfrenewal (Lengner et al., 2007) .
Establishment of models based on selection of cells upon self-renewal gene tracking allowed identification of TICs expressing Oct-4 in spontaneously developing tumours from p53À/À mice, thus overcoming the limitation of classical approaches. Our results provide new insights on the diversity of TICs and on their ability to produce secondary tumours. Our experimental model of disease should facilitate comprehension of the molecular mechanisms by which TICs produce metastasis and will be useful to target TICs via self-renewal genes directly supporting cancer development and endowed with a metastatic potential.
Materiels and methods

Reagents
Unless specified, all reagents were obtained from Sigma (Saint Quentin Fallavier, France).
Tissue culture media were from LONZA (Levallois-Perret, France) and foetal calf serum from Dutscher SA (Brumath, France).
Mouse model
Oct-4-GiP mice (Ying et al., 2002) express GFP and puromycin resistance under the direction of regulatory sequences of the mouse Oct-4 gene. This construct does not disturb endogenous Oct-4 expression and allows concomitant expressions of GFP, the puromycin resistance gene and Oct-4. They were bred with p53 invalidated mice (Donehower et al., 1992) . p53À/À mice bearing the Oct-4 transgene were selected after genotyping and they developed tumours within an average time comprising between 3-9 months. Animals were kept in our facility on a 12 h light-dark cycle with ad libitum access to food and water. Investigations were conducted according to the French and European rules for care and use of research animals. They were carried out under the supervision of certified researchers in accordance with good animal practice defined by the French 'Direction des Services Ve´te´rinaires'. Mice were killed by CO 2 asphyxiation.
Tumour isolation and cell culture Tumours were cut in different specimens. Histological analysis was performed on tumours fixed in formalin and embedded in paraffin. Sections were stained with haematoxylin, eosin and safranin.
Tumour cells were obtained by gentle mechanical dissociation after digestion in presence of collagenase (0.4 mg/ml; Roche Diagnostics, Meylan, France) and grown as murine ES cells at 37 1C in a humid atmosphere in presence of 5% CO 2 . The cultures were split at the log phase of cell growth to prevent overpopulation-induced cell death.
Oct-4-expressing cells were selected by incubating the cultures with puromycin (1 mg/ml) as described (Ying et al., 2002) .
Osteoblastic differentiation was induced by incubating confluent cells in an appropriate medium for 21 (analysis of markers) or 30 days (alizarin staining) and was assessed as previously described (Rodriguez et al., 2005) . Medium was changed every other day. Undifferentiated cells were incubated in the same conditions, but the differentiation cocktail was omitted.
Clonogenic assay Cells mixed into 5/6 Methocult GF 3434 (Stem cells Technologies, Grenoble, France) plus 1/6 complete culture medium (v/v) were plated onto Petri dishes. Colonies (450 cells) were scored after 30 days of incubation at 37 1C in a humidified chamber containing 5% CO 2 , as instructed by the manufacturer.
Induction of allografts and metastasis CB17/SCID mice (Charles River Laboratories, L'Arbresele, France) were used to assay the tumour potential of cells. Single-cell suspensions at passages 5 or 6 were prepared in a PBS-Matrigel (BD Bioscience, Le Pont de Claix, France) mixture (v/v) and injected in a 100 ml volume subcutaneously in the back of mice anesthetized with i.p. injection of ketamine/ xylazine (50 and 10 mg/kg, respectively). Mice were monitored biweekly during tumour development period lasting from 2 to 12 weeks and they were killed after 14 weeks when no tumour developed. Tumours were weighted and size was determined using ImageJ software (http://rsbweb.nih.gov/ij/). A portion of tumours was fixed into formalin 10% and then embedded in paraffin for histological analysis. Other part was used for cell isolation and culture.
Metastasis induction was performed by injection of singlecell suspensions in anesthetized CB17/SCID mice either in the lateral tail vein (10 6 cells/0.2 ml in phosphate-buffered saline) or i.p. (0.25 Â 10 6 to 10 6 cells in phosphate-buffered saline). Mice were then evaluated twice weekly for any sign of emaciation, respiratory stress or lethargy. Mice were killed as soon as evidences of incapacitating tumour burden were detected. Organs were resected and submitted to histological analysis.
Mouse imaging
Bioluminescent imaging of inoculated cells was performed using an in vivo Imaging System (IVIS 100; Caliper LifeScience, Villepinte, France). Before imaging, CB17/SCID mice were anesthetized in a chamber with a 1.5% (v/v) isoflurane/air mixture and i.p. injected with luciferin (150 mg/kg body weight). In vivo scanning was also performed using a SkyScan 1178 (SkyScan, Kontich, Belgium). Micro-CT was performed using digital X-ray camera, which scanned over 1801 at a resolution of 83 mm, 50 kV, 615 mA.
Validation of the data obtained by bioimaging to assess extend of tumour metastasis was performed after autopsies of killed mice by CO 2 inhalation.
Gene expression analysis, western blotting, RNA interference experiments and immunocytochemistry analysis were performed as described in Supplementary Material.
Statistical analysis
Results are shown as mean ± s.e.m., with number of experiments indicated. Statistical significance was determined by t-tests or analysis of variance using Micrococal Origin 6.0 (Micrococal Software, Northampton, MA, USA). Probability values o0.05 were considered as statistically significant and are marked with a single asterisk, o0.01 by double asterisks and o0.001 by triple asterisks.
